Autologous serum eye drops for the treatment of ocular surface disease

Eye and Contact Lens

Volumn 41, Issue 3, 2015, Pages 133-140

  Azari, Amir A ^a   Rapuano, Christopher J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Autologous serum drops

Indexed keywords

AUTOLOGOUS SERUM EYE DROP; EYE DROPS; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ANEMIA; ANIRIDIA; BIOLOGICAL ACTIVITY; CLINICAL EXAMINATION; CORNEA EROSION; CORNEA PERFORATION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRY EYE; EYE DISCOMFORT; EYE INFECTION; GRAFT VERSUS HOST REACTION; HAEMOPHILUS INFECTION; HUMAN; IMPRESSION CYTOLOGY; KERATITIS; KERATOCONJUNCTIVITIS; OCULAR SURFACE DISEASE; PRIORITY JOURNAL; REVIEW; SJOEGREN SYNDROME; SKIN DEFECT; TREATMENT OUTCOME; CORNEAL DISEASES; DRY EYE SYNDROMES; SERUM;

CORNEAL DISEASES; DRY EYE SYNDROMES; HUMANS; OPHTHALMIC SOLUTIONS; SERUM;

EID: 84929049316     PISSN: 15422321     EISSN: 1542233X     Source Type: Journal    
DOI: 10.1097/ICL.0000000000000104     Document Type: Review

References (54)

1. Ralph RA, Doane MG, Dohlman CH. Clinical experience with a mobile ocular perfusion pump. Arch Ophthalmol 1975;93:1039-1043.
2. Fox RI, Chan R, Michelson JB, et al. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum 1984;27:459-461.
3. Tsubota K, Goto E, Shimmura S, et al. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology 1999;106:1984-1989.
4. Tsubota K, Goto E, Fujita H, et al. Treatment of dry eye by autologous serum application in Sjogren's syndrome. Br J Ophthalmol 1999;83: 390-395.
5. Ohashi Y, Motokura M, Kinoshita Y, et al. Presence of epidermal growth factor in human tears. Invest Ophthalmol Vis Sci 1989;30:1879-1882.
6. Gupta A, Monroy D, Ji Z, et al. Transforming growth factor beta-1 and beta-2 in human tear fluid. Curr Eye Res 1996;15:605-614.
7. Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol 2004;88:1467-1474.
8. Pan Q, Angelina A, Zambrano A, et al. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev 2013;8:CD009327.
9. Welder JD, Bakhtiari P, Djalilian AR. Limbitis secondary to autologous serum eye drops in a patient with atopic keratoconjunctivitis. Case Rep Ophthalmol Med 2011;2011:576521.
10. Lekhanont K, Jongkhajornpong P, Choubtum L, et al. Topical 100 serum eye drops for treating corneal epithelial defect after ocular surgery. Biomed Res Int 2013;2013:521315.
11. Pflugfelder SC, Corrales RM, de Paiva CS. T helper cytokines in dry eye disease. Exp Eye Res 2013;117:118-125.
12. Amemiya T. The eye and nutrition. Jpn J Ophthalmol 2000;44:320.
13. Sommer A. Effects of vitamin A deficiency on the ocular surface. Ophthalmology 1983;90:592-600.
14. Cho HK, Park MH, Moon JI. The effect of additional topical cyclosporine or vitamin A on the ocular surface during antiglaucoma medication administration. Ophthalmic Res 2012;48:139-145.
15. Kim EC, Choi JS, Joo CK. A comparison of vitamin a and cyclosporine a 0.05 eye drops for treatment of dry eye syndrome. Am J Ophthalmol 2009;147:206-213.e3.
16. Peponis V, Papathanasiou M, Kapranou A, et al. Protective role of oral antioxidant supplementation in ocular surface of diabetic patients. Br J Ophthalmol 2002;86:1369-1373.
17. Bilgihan K, Adiguzel U, Sezer C, et al. Effects of topical vitamin E on keratocyte apoptosis after traditional photorefractive keratectomy. Ophthalmologica 2001;215:192-196.
18. Nakamura M, Sato N, Chikama T, et al. Fibronectin facilitates corneal epithelial wound healing in diabetic rats. Exp Eye Res 1997;64:355-359.
19. Nishida T, Nakagawa S, Nishibayashi C, et al. Fibronectin enhancement of corneal epithelial wound healing of rabbits in vivo. Arch Ophthalmol 1984;102:455-456.
20. Kojima T, Higuchi A, Goto E, et al. Autologous serum eye drops for the treatment of dry eye diseases. Cornea 2008;27(Suppl 1):S25-S30.
21. Lambiase A, Rama P, Bonini S, et al. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med 1998;338:1174-1180.
22. Wang L, Wu X, Shi T, et al. Epidermal growth factor (EGF)-induced corneal epithelial wound healing through nuclear factor kappaB subtyperegulated CCCTC binding factor (CTCF) activation. J Biol Chem 2013;288: 24363-24371.
23. Watson SL, Secker GA, Daniels JT. The effect of therapeutic human serum drops on corneal stromal wound-healing activity. Curr Eye Res 2008;33: 641-652.
24. Liou LB. Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients. Clin Exp Rheumatol 2001;19:515-523.
25. Okanobo A, Chauhan SK, Dastjerdi MH, et al. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol 2012;154:63-71.
26. Ogawa Y, Okamoto S, Mori T, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transpl 2003;31:579-583.
27. Poon AC, Geerling G, Dart JK, et al. Autologous serum eyedrops for dry eyes and epithelial defects: Clinical and in vitro toxicity studies. Br J Ophthalmol 2001;85:1188-1197.
28. Jeng BH, Dupps WJ Jr. Autologous serum 50 eyedrops in the treatment of persistent corneal epithelial defects. Cornea 2009;28:1104-1108.
29. Schulze SD, Sekundo W, Kroll P. Autologous serum for the treatment of corneal epithelial abrasions in diabetic patients undergoing vitrectomy. Am J Ophthalmol 2006;142:207-211.
30. Chen YM, Hu FR, Huang JY, et al. The effect of topical autologous serum on graft re-epithelialization after penetrating keratoplasty. Am J Ophthalmol 2010;150:352-359.e2.
31. Fernando AI, Burton BJ, Smith GT, et al. Autologous serum dropdependent re-epithelialisation following penetrating keratoplasty in chronic graft vs host disease. Eye 2005;19:823-825.
32. Alvarado Valero MC, Martinez Toldos JJ, Borras Blasco J, et al. Treatment of persistent epithelial defects using autologous serum application. Arch Soc Esp Oftalmol 2004;79:537-542.
33. Young AL, Cheng AC, Ng HK, et al. The use of autologous serum tears in persistent corneal epithelial defects. Eye 2004;18:609-614.
34. Na KS, Kim MS. Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease. J Ocul Pharmacol 2012;28: 479-483.
35. Rocha EM, Pelegrino FS, de Paiva CS, et al. GVHD dry eyes treated with autologous serum tears. Bone Marrow Transpl 2000;25:1101-1103.
36. Tananuvat N, Daniell M, Sullivan LJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea 2001;20:802-806.
37. Noble BA, Loh RS, MacLennan S, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol 2004;88:647-652.
38. Kojima T, Ishida R, Dogru M, et al. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: A prospective randomized case-control study. Am J Ophthalmol 2005;139:242-246.
39. Lee GA, Chen SX. Autologous serum in the management of recalcitrant dry eye syndrome. Clin Exp Ophthalmol 2008;36:119-122.
40. Harritshoj LH, Nielsen C, Ullum H, et al. Ready-made allogeneic ABOspecific serum eye drops: Production from regular male blood donors, clinical routine, safety and efficacy. Acta Ophthalmol 2014;92:783-786.
41. Urzua CA, Vasquez DH, Huidobro A, et al. Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome. Curr Eye Res 2012;37:684-688.
42. Jirsova K, Brejchova K, Krabcova I, et al. The application of autologous serum eye drops in severe dry eye patients;subjective and objective parameters before and after treatment. Curr Eye Res 2014;39:21-30.
43. Fuchsluger TA, Steuhl KP, Meller D. Neurotrophic keratopathy-a post-LASIK case report. Klin Monbl Augenheilkd 2005;222:901-904.
44. Noda-Tsuruya T, Asano-Kato N, Toda I, et al. Autologous serum eye drops for dry eye after LASIK. J Refract Surg 2006;22:61-66.
45. Lopez-Garcia JS, Rivas L, Garcia-Lozano I, et al. Autologous serum eyedrops in the treatment of aniridic keratopathy. Ophthalmology 2008;115: 262-267.
46. Holzer MP, Auffarth GU, Specht H, et al. Combination of transepithelial phototherapeutic keratectomy and autologous serum eyedrops for treatment of recurrent corneal erosions. J Cataract Refract Surg 2005;31:1603-1606.
47. Ziakas NG, Boboridis KG, Terzidou C, et al. Long-term follow up of autologous serum treatment for recurrent corneal erosions. Clin Exp Rheumatol 2010;38:683-687.
48. Goto E, Shimmura S, Shimazaki J, et al. Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea 2001;20: 807-810.
49. Leite SC, de Castro RS, Alves M, et al. Risk factors and characteristics of ocular complications, and efficacy of autologous serum tears after haematopoietic progenitor cell transplantation. Bone Marrow Transpl 2006;38: 223-227.
50. Sanz-Marco E, Lopez-Prats MJ, Garcia-Delpech S, et al. Fulminant bilateral Haemophilus influenzae keratitis in a patient with hypovitaminosis A treated with contaminated autologous serum. Clin Ophthalmol 2011;5:71-73.
51. McDonnell PJ, Schanzlin DJ, Rao NA. Immunoglobulin deposition in the cornea after application of autologous serum. Arch Ophthalmology 1988;106:1423-1425.
52. Jeng BH. Use of autologous serum in the treatment of ocular surface disorders. Arch Ophthalmol 2011;129:1610-1612.
53. Dalmon CA, Chandra NS, Jeng BH. Use of autologous serum eyedrops for the treatment of ocular surface disease: First US experience in a large population as an insurance-covered benefit. Arch Ophthalmol 2012;130:1612-1613.
54. Cho YK, Huang W, Kim GY, et al. Comparison of autologous serum eye drops with different diluents. Curr Eye Research 2013;38:9-17.